

Bioactive peptides. Formulations and indications

Rick Visser



University of Malaga




Maastricht, 2022




Cells need instructions



Most cells are blind & deaf...
...but they can feel and smell



Cells need instructions, also in (Bone) Tissue Engineering



The added bioactive elements (& the biomaterial) should provide instructions for the cells:

- Come here!
- Stay here!
- Attach to this!
- Multiply!
- Form bone, or cartilage, or blood vessels!

Many instructions are encoded in large, complex proteins

The diagram illustrates a protein structure composed of a central grey backbone and blue and grey side chains. At the top left, a carboxyl group (COOH) is shown at the top, and an amino group (NH₂) is at the bottom. The protein is depicted as a spiral chain interacting with a grey horizontal bar representing a 'cell membrane'. Below the membrane, two purple semi-circular shapes represent receptor proteins embedded in it. A blue arrow points from the protein structure towards the right, where a blue thumbs-up icon is positioned above a bulleted list of advantages. Another blue arrow points downwards from the protein structure, leading to a blue thumbs-up icon on the left and a bulleted list of advantages. On the right, a grey thumbs-down icon is positioned above a bulleted list of disadvantages.

Advantages (Blue Thumbs-Up):

- More stable
- Cheaper
- Less immunogenic
- Specific
- Smaller size allows for higher densities
- Smaller size allows for easier encapsulation

Disadvantages (Grey Thumbs-Down):


- **Lower activity**
- Poorly characterized
- Many not commercially available

Are peptides always better?

Definitely, not! (but sometimes they can be)


- High activity
- Well characterized
- Commercially available

- Sensitive
- Expensive
- Immunogenic
- Binding sites for other receptors/cells. Pleiotropy




What to consider when approaching a (B)TE strategy involving peptides...

How will the peptide act/interact with it's receptors?




Does it need anchorage to a surface?

Does it need a specific density or spatial distribution?




Does it need to be released?



Does it need a delayed or triggered release?

Peptide name	Sequence	Source
RGD	XRGDX	Fibronectin, osteopontin, BSP and others
pRGD / bsp-RGD	CGGN E PRGDTYRAY	BSP
hBSP ₂₇₈₋₂₉₃	YESEN G EPRGDNYRAY	BSP
PHSRN	PHSRN	Fibronectin
F105	YKRSRYT	FGF-2
F119	KRTGQYKLGSKTGPGQK	FGF-2
F36	PDGRVD	FGF-2
F77	KEDGRLL	FGF-2
GFOGER	GGYGGG P C(GPP) ₅ GFOGER(GPP) ₅ GPC	Collagen type I
DGEA	DGEA	Collagen type I
P15	GTPGPQGIAGQRGVV	Collagen type I
AC-100	ERGDNDISPFGDGQ	MEPE
ODP (osteopontin-derived peptide)	DVDVPDGRGDSLAYG	Osteopontin
RRETAWA	RRETAWA	Identified by phage display
YIGSR	YIGSR	Laminin
IKVAV	IKVAV	Laminin
Ln2-P3	DLTI D DSVWYRI	Laminin
KRSR	KRSR	BSP, fibronectin, osteopontin and others
Consensus heparin binding domain	FHRR IKA	BSP
HBD peptide	RKKNPNCRRH	BMP-4
BMP-2-derived peptide	NSVNSKIPKACCVPTELSAI	BMP-2
BMP-2-derived peptide	KIPKASSVPTELSAISTLYL	BMP-2
P24	S ^[PO4] KIPKASSVPTELSAISTLYL DDD	BMP-2
pBMP-9 / SpBMP-9	CGGKV G KA(CC/SS)VPTKLSPISVLYK	BMP-9
BMP-9-derived peptide	RKV G KASSVPTKLSPISILYK	BMP-9
BMP-7-derived peptide	RTVPKPSSA P TQLNAISTLYF	BMP-7
BFP-1	GQGF S YPYKAVFSTQ	BMP-7
OPD (osteopromotive domain)	DWIVA	BMP-2
CBM	GLRSKSKKFRRPDIQYPDATDEDITSHM	Osteopontin
BCSP™-1	NGLPGPIGP	Collagen type I
OGP (osteogenic growth peptide)	ALKRQGRTLYGFGG	Naturally occurring
OGP ₁₀₋₁₄	YFGGG	OGP
PTH ₁₋₃₄	SVSEIQLMHNLGKHLSMERVEWLKKLQDVHN F	Parathyroid hormone
CB	NGVFKYPRYYLYK H AYFYPHLKRFPVQ	BSP
CTC peptide	IAGVG G EKGSGGF	Collagen IIIa
Substance P	RPKPQQFFGLM	Naturally occurring
Endothelin-1	CSCSSLMDKECVYFC H LDDIIW	Naturally occurring
QK	KLTWQELYQLKYKGI	VEGF
PBA2-1c	(CVRKIEIVRK K) ₂ -Ahx-Ahx-Ahx-RKRKLERIAR	PDGF
Exendin 4	HGETGFTSDLSKQMEEAVRLFIEWLKNGGPSSGAPPS	Glucagon-like peptide
OPD (osteopontin-derived peptide)	SVVYGLR	Osteopontin
SPARC 113	TLEGTKKGHLHDY	Osteonectin
SPARC 118	KKGHK	Osteonectin
TP508	AGYKPDEGKRG D ACEGDSGGPFV	Thrombin
RoY	YPHIDSLGHWR R	Designed
LL-37	LLGDFFRKSKEKIGKEFKRIVQRIKDFRLNLVPRTES	hCAP18



peptides derived from ECM proteins

adhesion vs. other bioactivities


RGD - PHSRN

P-15

DGEA

YIGSR

GFOGER



other peptides

natural peptides, hormone-derived
peptides, cathelicidins

PTH₁₋₃₄ (teriparatide)



peptides derived from BMPs

chondro- / osteoinduction

Peptides derived from angiogenic factors

angiogenesis

A personal experience



Visser *et al.*, 2014
Visser *et al.*, 2016
Rico-Llanos, 2018

